Catherine Roche-Lestienne
Cancer Research Institute of Lille
JP Aubert Center
Inserm Unit 837
France
Name/email consistency: high
- RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Roche-Lestienne, C., Deluche, L., Corm, S., Tigaud, I., Joha, S., Philippe, N., Geffroy, S., Laï, J.L., Nicolini, F.E., Preudhomme, C. Blood (2008)